Reuters reported Wednesday that U.S. regulators would look at data from previous clinical trials that came from the same scientists who created the vaccine, AZD1222, which originated at the University of Oxford and is also known as ChAdOx1 nCoV-19.
The New York Times had reported that the participant in question was taking part in a Phase II/III trial in the U.K. The event was reported the same day that AstraZeneca's CEO and nine others signed a pledge not to rush development of vaccines against the SARS-CoV-2 virus.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
The company announced the publication of interim data from the Phase I/II study of a vaccine it is developing with the University of Oxford. The news comes the week after Moderna announced the publication of data for its vaccine.
The drugmaker licensed the vaccine last month from the University of Oxford, which is developing it in a Phase I/II clinical trial in southern England. The company also plans a Phase III study.
The drugmaker is partnering with Oxford to develop the adenovirus vector-based vaccine, ChAdOx1 nCoV-19, which entered a Phase I/II clinical trial of more than 1,100 healthy volunteers in the U.K. late last month. Data could be available next month, the company said.